Cannabics Pharmaceuticals (OTCQB: CNBX), a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has filed a provisional patent application with the US Patent office.
| TEL AVIV, Israel and BETHESDA, Maryland /PRNewswire/ -- Cannabics Pharmaceuticals (OTCQB: CNBX), a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has filed a provisional patent application with the US Patent office.  The patent covers the Company’s novel delivery system designed specifically for personalized targeted cannabinoid-based therapy. The title of the filing is “A System and Method for Providing Magnetic targeting of Cannabinoids to Cancer Patients”. This cutting-edge technology fuses specific cannabinoids to iron particles through molecular bonding, which can then be targeted to a specific physical location in the patient’s body. This innovative non-invasive approach allows internal systemic delivery of cannabinoids to the actual area of live tumors within the patient. This is one of several recent patents which has made Cannabics Pharmaceuticals one of the world’s leaders in the emerging field of targeted personalized medicine. Dr. Eyal Ballan, Co-Founder and CTO, said: “We are pleased to continue and re-affirm our aggressive approach towards cannabinoid-based therapies by strengthening our IP portfolio with novel and unique technologies.” Cannabics Pharmaceutical recently launched their state-of-the-art new laboratory in Israel. “We are looking forward to sharing more developments with public as they unfold.” About Cannabics Pharmaceuticals Headquartered in Tel-Aviv, Israel, Cannabics Pharmaceuticals Inc. (CNBX) is a U.S public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient’s profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The company’s R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and Cancer. For the latest updates on Cannabics Pharmaceuticals follow the company on twitter @cannabics1, facebook @CannabicsPharmaceuticals and LinkedIn. For more information about Cannabics visit www.Cannabics.com For further information, please contact: Cannabics Pharmaceuticals Inc.
SOURCE Cannabics Pharmaceuticals Inc. | ||
Company Codes: Munich:8C8, OTC-PINK:CNBX, OTC-QB:CNBX, OtherOTC:CNBX, Stuttgart:8C8 |
View original content:
